Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial

NCT05016882 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT05016882
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05016882 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety Investigation of NNC0194-0499 Co-administered With Semaglutide in Subjects With Non-alcoholic Steatohepatitis: a Dose-ranging, Placebo Controlled Trial
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2021
Completion date
March 14, 2025
Enrollment
698 (actual)
Sites
255

Conditions

As the registry lists them; a condition with its own page is linked.

non-alcoholic steatohepatitis